ENTA Quote, Financials, Valuation and Earnings

Agios Pharmaceuticals, Inc. has a net margin of -64.13% compared to Enanta Pharmaceuticals, Inc.'s net margin of -541.09%. Enanta Pharmaceuticals, Inc.'s return on equity of -75.15% beat Agios Pharmaceuticals, Inc.'s return on equity of -30.11%.

Enanta Pharmaceuticals, Inc. has a consensus price target of $20.25, signalling upside risk potential of 41.61%. On the other hand Agios Pharmaceuticals, Inc. has an analysts' consensus of $38.88 which suggests that it could grow by 28.6%. Given that Enanta Pharmaceuticals, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Enanta Pharmaceuticals, Inc. is more attractive than Agios Pharmaceuticals, Inc..

Enanta Pharmaceuticals, Inc. has a beta of 0.982, which suggesting that the stock is 1.803% less volatile than S&P 500. In comparison Agios Pharmaceuticals, Inc. has a beta of 0.915, suggesting its less volatile than the S&P 500 by 8.508%.

Enanta Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agios Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Agios Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals, Inc. quarterly revenues are $18.6M, which are smaller than Agios Pharmaceuticals, Inc. quarterly revenues of $20M. Enanta Pharmaceuticals, Inc.'s net income of -$11.9M is higher than Agios Pharmaceuticals, Inc.'s net income of -$108M. Notably, Enanta Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Agios Pharmaceuticals, Inc.'s PE ratio is 3.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals, Inc. is 4.96x versus 32.43x for Agios Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alnylam Pharmaceuticals, Inc. has a net margin of -64.13% compared to Enanta Pharmaceuticals, Inc.'s net margin of 16.99%. Enanta Pharmaceuticals, Inc.'s return on equity of -75.15% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Enanta Pharmaceuticals, Inc. has a consensus price target of $20.25, signalling upside risk potential of 41.61%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.27%. Given that Enanta Pharmaceuticals, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Enanta Pharmaceuticals, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Enanta Pharmaceuticals, Inc. has a beta of 0.982, which suggesting that the stock is 1.803% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

Enanta Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals, Inc. quarterly revenues are $18.6M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Enanta Pharmaceuticals, Inc.'s net income of -$11.9M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Enanta Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 147.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals, Inc. is 4.96x versus 11.97x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

BioMarin Pharmaceutical, Inc. has a net margin of -64.13% compared to Enanta Pharmaceuticals, Inc.'s net margin of -5.33%. Enanta Pharmaceuticals, Inc.'s return on equity of -75.15% beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.

Enanta Pharmaceuticals, Inc. has a consensus price target of $20.25, signalling upside risk potential of 41.61%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.17 which suggests that it could grow by 42.84%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Enanta Pharmaceuticals, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Enanta Pharmaceuticals, Inc..

Enanta Pharmaceuticals, Inc. has a beta of 0.982, which suggesting that the stock is 1.803% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.

Enanta Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals, Inc. quarterly revenues are $18.6M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $874.6M. Enanta Pharmaceuticals, Inc.'s net income of -$11.9M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, Enanta Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 34.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals, Inc. is 4.96x versus 3.73x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Savara, Inc. has a net margin of -64.13% compared to Enanta Pharmaceuticals, Inc.'s net margin of --. Enanta Pharmaceuticals, Inc.'s return on equity of -75.15% beat Savara, Inc.'s return on equity of -78.83%.

Enanta Pharmaceuticals, Inc. has a consensus price target of $20.25, signalling upside risk potential of 41.61%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 79.61%. Given that Savara, Inc. has higher upside potential than Enanta Pharmaceuticals, Inc., analysts believe Savara, Inc. is more attractive than Enanta Pharmaceuticals, Inc..

Enanta Pharmaceuticals, Inc. has a beta of 0.982, which suggesting that the stock is 1.803% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.

Enanta Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals, Inc. quarterly revenues are $18.6M, which are larger than Savara, Inc. quarterly revenues of --. Enanta Pharmaceuticals, Inc.'s net income of -$11.9M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Enanta Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals, Inc. is 4.96x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.